Table 1. Receiver operating characteristic curves of CONCORD prediction on independent validation cohorts.
| Drug | Cancer Type |
Validation Cohort |
AUC (SE) | P-value | 95% Confidence Interval of AUC |
|---|---|---|---|---|---|
| Paclitaxel | Breast | Hess-133 | 0.724 (0.048) | < 0.001 | [0.629, 0.818] |
| Horak-127 | 0.663 (0.055) | 0.005 | [0.556, 0.77] | ||
| Tabchy-91 | 0.681 (0.066) | 0.016 | [0.552, 0.81] | ||
| Ovarian | TCGA-448 | 0.602 (0.035) | 0.004 | [0.534, 0.671] | |
| UVA-51 | 0.725 (0.072) | 0.006 | [0.584, 0.867] | ||
| Dressman-119 | 0.647 (0.054) | 0.013 | [0.54, 0.753] | ||
| 5-FU | Breast | Tabchy-178 | 0.626 (0.06) | 0.041 | [0.509, 0.743] |
| Hess-133 | 0.620 (0.057) | 0.037 | [0.508, 0.733] | ||
| Iwamoto-82 | 0.644 (0.066) | 0.041 | [0.514, 0.774] | ||
| Gastric | Kim-97 | 0.671 (0.065) | 0.015 | [0.543, 0.799] | |
| Adriamycin | Breast | Horak-265 | 0.605 (0.047) | 0.035 | [0.513, 0.696] |
| Tabchy-178 | 0.628 (0.062) | 0.038 | [0.505, 0.75] | ||
| Hess-133 | 0.654 (0.058) | 0.008 | [0.539, 0.768] | ||
| Iwamoto-82 | 0.72 (0.061) | 0.002 | [0.6, 0.84] | ||
| Lymphoma | Steidl-130 | 0.601 (0.052) | 0.07 | [0.5, 0.703] | |
| Hummel-110 | 0.666 (0.051) | 0.003 | [0.565, 0.767] |
Sensitivity and specificity of CONCORD prediction scores for predicting complete response outcomes in patients of each validation cohort were used to calculate the area under a receiver operating characteristic curve (AUC), standard error (SE), and 95% confidence interval of AUC. P-value is a result of significance test of AUC against a null hypothesized AUC of 0.5, which means a random prediction.